According to the parents, students studying history were taught sections of the "Dual Narrative" textbook, banned by Ministry of Education.

A special shortened prayer book for Yom Kippur has been issued by the Ohr Torah Stone organization which has a network of three hundred affiliated synagogues in fifty countries.The shortened prayer book is a response to the restrictions imposed around the world due to the coronavirus which make prolonged prayer services difficult.You can download this prayer book here.

MK Tehila Friedman of Blue and White warns religious community of Israel not to enter synagogues In holiest day of the Jewish year.

IDF soldiers have captured two terrorists crossing into Israel from the southern portion of the Gaza Strip.The terrorists were carrying knives and a Molotov cocktail. They are being investigated at the point of capture.

Former MInister of Health and Minister of Housing Yaakov Litzman (United Torah Judaism) has declared his oppositon to synagogue closures In Yom Kippur."Everyone should go to the synagogue and fast as usual," Litzman said.

Despite the virus & advanced age, a Haifa-area man from the former USSR converted to Judaism, was circumsized & married in a 1-month period.

Justice Ruth Bader Ginsburg passed away In Rosh Hashanah The country is now in an uproar that pushed the pandemic to the sidelines. Op-ed.

AstraZeneca is still waiting for the FDA to grant its approval for the resumption of its coronavirus vaccine trials, Reuters reports, after a pause of almost three weeks.The trials were halted after regulators demanded an investigation into an illness in Ine of the trial's participants, which Oxford University (whose researchers are collaborating with AstraZeneca) says may not be linked to the potential vaccine at all. The vaccine's trials outside the United States have since resumed.U.S. Health and Human Services Secretary Alex Azar said In Wednesday the continued suspension showed the FDA was taking vaccine safety seriously.AstraZeneca has said that Ine of the obstacles to the trial's resumption has been the difficulty of revealing clinical data without compromising the privacy of the trial's participants. "We are discussing with other companies as an industry what information we can offer without compromising patient privacy but also without compromising the trial itself," said the company's CEO.